free web stats

Law Offices of Thomas J. Lamb

Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect

By

There is a significant development concerning semaglutide drugs like Ozempic linked to vision loss and blindness:

The European Union’s drug regulator said it would assess two new Danish studies that link Novo Nordisk’s popular diabetes drug Ozempic to a rare eye disease.

The studies published earlier this week had found Ozempic significantly increases the risk of type 2 diabetes patients developing NAION (non-arteritic anterior ischemic optic neuropathy), more than doubling the likelihood. [emphasis added]

This comes from the December 18, 2024, Reuters news report, “Novo Nordisk’s Ozempic faces EU review for potential eye disease connection”.

How this new investigation of Ozempic linked to vision loss by the European Committee for the Evaluation of Adverse Reactions, or PRAC, came about is explained by this December 16, 2024, Bloomberg article, “Ozempic Blinding Link in Study Prompts Agency to Seek Probe”:

The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between Novo Nordisk A/S’s blockbuster shot Ozempic and a rare form of vision loss…

A pair of large studies from the University of Southern Denmark “strengthen the suspicion” of a link between Ozempic and the rare eye condition, called NAION, the agency said.

Conducted independently, the studies both found that people who took Ozempic faced more than twice the risk of the eye condition, which can cause blindness. Both appear to confirm a link first suggested earlier this year in a Harvard University study…. [emphasis added]

Besides Ozempic, this vision loss side effect is possible with Wegovy and Rybelsus because, like Ozempic, the active ingredient for these other two Novo Nordisk drugs is semaglutide. It is semaglutide specifically that has been associated with nonarteritic anterior ischemic optic neuropathy (NAION) in several medical studies to date.

People who have been diagnosed with NAION after their use of the use of Ozempic, Wegovy, or Rybelsus and experienced vision loss may be entitled to legal compensation by filing a drug injury lawsuit against Novo Nordisk.

We point out that NAION is sometimes referred to more simply as an “eye stroke” and, as it is a form of “optic neuropathy” (an eye disease category), NAION may be noted only as optic neuropathy in the medical records.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus

By

We have been receiving reports of people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), and ischemic stroke possibly due to semaglutide-related blood clots. Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.

Semaglutide-Related Blood Clots Cases: DVT and Pulmonary Embolism

Here are some reports of DVT and pulmonary embolism involving semaglutide drugs we have received in the past several months:

Ozempic – Deep vein thrombosis (DVT) and pulmonary embolism were diagnosed in a 66-year-old woman who had been using Ozempic for 2 months.

Ozempic – Pulmonary embolism (PE) and DVT were diagnosed in a 53-year-old man who had been using Ozempic for 1 year.

Ozempic – Blood clots in both lungs, which is a bilateral pulmonary embolism, were diagnosed in a 46-year-old woman who had been using Ozempic for 2 months.

Rybelsus – DVT was diagnosed in a 62-year-old woman who had been using Rybelsus for 1 month.

Semaglutide-Related Blood Clots Cases: Other Medical Conditions

Here are some reports of other blood clot conditions involving semaglutide drugs we have received in the past several months:

Ozempic – Blood clot in the portal vein, or portal vein thrombosis (PVT), was diagnosed in a 44-year-old woman who had been using Ozempic for 2 weeks.

Wegovy – Ischemic stroke was diagnosed in a 45-year-old man who had been using Wegovy for 3 months.

We are investigating possible Rybelsus, Wegovy, and Ozempic drug injury lawsuits for people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), ischemic stroke, or any other blood clot-related side effects.

Let us know if we can assist you or someone you know with a Wegovy, Rybelsus, or Ozempic blood clot case. One way to do this is to submit an online Case Evaluation Form.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic Side Effects Include Eye Problems With Possible Vision Loss

By

In July 2024 we learned from a recent medical study that Ozempic side effects include eye problems with possible vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide — the active ingredient in Ozempic as well as Wegovy and Rybelsus. As such, this finding about the new NAION Ozempic eye problems side effects also applies to Wegovy and Rybelsus.

The medical study that found the new Ozempic eye problems side effects was presented in this article, “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide”, which was published on July 3, 2024, by the medical journal JAMA Ophthalmology.

We get an overview of the semaglutide – NAION medical study from this July 3, 2024, STAT news article, “Study links Ozempic to a higher risk of eye condition that can cause vision loss”:

A new observational study on [July 3, 2024] reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss….

NAION, sometimes referred to as an “eye stroke,” occurs from a lack of sufficient blood flow to the optic nerve. It typically causes sudden vision loss and, in severe cases, can lead to blindness. There are currently no proven treatments for the condition.

Some information about the increased risk of these Wegovy, Rybelsus, and Ozempic eye problems side effects was provided in this July 3, 2024, MedPage Today article, “Semaglutide May Be Linked to Condition That Causes Blindness”:

Over a mean follow-up of nearly 3 years, patients with diabetes on semaglutide had more than a fourfold higher risk for developing nonarteritic anterior ischemic optic neuropathy (NAION) compared with patients not on a GLP-1 agonist (HR 4.28, 95% CI 1.62-11.29, P<0.001)….

Those prescribed semaglutide for overweight or obesity had an over sevenfold higher risk for NAION (HR 7.64, 95% CI 2.21-26.36, P<0.001), a significant cause of blindness…

Over 3 years, the cumulative incidence of NAION were 8.9% and 6.7% in the two semaglutide groups, respectively, versus 1.8% and 0.8% for the non-GLP-1 groups. [emphasis added]

Relevant to this recent finding that Ozempic side effects include eye problems with possible vision loss, we point out that in medical records, NAION is sometimes referred to more simply as an “eye stroke” and because it is a form of “optic neuropathy” (an eye disease category) NAION might be noted in short only as optic neuropathy.

Patients who developed NAION following the use of Ozempic, Wegovy, or Rybelsus may be entitled to legal compensation by filing a drug injury lawsuit against Novo Nordisk, the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic

By

Drug injury lawsuits that might be filed against the pharmaceutical company Novo Nordisk involving a stroke, pulmonary embolism, or deep vein thrombosis when using Wegovy, Rybelsus, or Ozempic are somewhat like the federal court Wegovy/Rybelsus/Ozempic MDL lawsuits involving gastrointestinal and stomach problems because they would involve similar — but different — liability issues, such as:

  • Whether Novo Nordisk knew or should have known that its semaglutide-containing drugs Wegovy, Rybelsus, and Ozempic can cause ischemic strokes (which are strokes caused by blood clots), pulmonary embolism (PE), or deep vein thrombosis (DVT) — as opposed to gastroparesis, gastric stasis, stomach paralysis, and other semaglutide-related stomach conditions;
  • Whether Novo Nordisk adequately warned the patient or their prescribing doctor about the alleged increased risk of blood clots of Wegovy, Rybelsus, Ozempic that can lead to a stroke, PE, or DVT; and,
  • Whether Novo Nordisk made false, misleading, or incomplete representations regarding the drug safety of Wegovy, Rybelsus, and Ozempic.

In more detail, drug injury lawsuits for people using Wegovy, Rybelsus, or Ozempic diagnosed with gastroparesis, gastric stasis, stomach paralysis, and other semaglutide-related stomach conditions are in this federal court MDL: IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION, MDL No. 3094.

However, drug injury lawsuits involving a stroke, pulmonary embolism, or deep vein thrombosis when using Wegovy, Rybelsus, or Ozempic would not be part of federal court MDL No. 3094 as currently configured in the February 2024 Transfer Order because that federal court MDL does not include stroke, PE, and DVT cases.

We have been investigating possible drug injury lawsuits against Novo Nordisk involving strokes caused by blood clots as well as PEs and DVTs in patients using Wegovy, Rybelsus, or Ozempic.

If we can assist you or someone you know, our Drug Injury Case Evaluation Form is available online, or you can call us at (800) 426-9535 to discuss a possible Wegovy, Rybelsus, or Ozempic case.

[Read article in full at original source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects

By

Adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis associated with Ozempic, Wegovy, and Rybelsus, the three popular GLP-1 receptor agonists containing semaglutide used as weight-loss drugs, are relatively well-known by now. In comparison, Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects have not received much attention.

Remarkably, medical researchers found that semaglutide — and therefore Wegovy, Rybelsus, and Ozempic — increased the risk of deep vein thrombosis (DVT) by 266% in patients with type 2 diabetes. The medical journal article that reported this semaglutide DVT side effect finding is “Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials”, published by the Endocrine Journal back in 2021.

Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects are particularly alarming since patients who have type 2 diabetes and who are obese are already at an increased risk of DVT. Significantly, the authors of this 2021 Endocrine Journal article suggested that Ozempic, Rybelsus, and Wegovy perhaps should be avoided by obese people with type 2 diabetes patients due to this semaglutide DVT side effect finding.

Here is some medical information about deep vein thrombosis (also known as deep venous thrombosis) from the Mayo Clinic, the U.S. National Institute of Health’s Medline Plus, and the Centers for Disease Control and Prevention.

We are investigating possible drug injury lawsuits involving Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects.

[Read article in full at original source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity

By

To start, we point out two medical journal articles that present a few weight-loss drugs gastroparesis side effects reports involving the use of semaglutide (Ozempic, Rybelsus, Wegovy) or dulaglutide (Trulicity):

  1. Tendency of Semaglutide to Induce Gastroparesis: A Case Report
  2. Medication-Induced Gastroparesis: A Case Report

Significantly, these medical journal articles provide some helpful information about symptoms and diagnosis of the weight-loss drugs gastroparesis side effects that have been associated with Ozempic, Rybelsus, Wegovy, and Trulicity.

In the past six months on our Drug Injury Watch blog, we have written several times about the weight-loss drugs gastroparesis side effects:

Ozempic / Wegovy: Stomach And Intestinal Problems Can Be Irreversible, Life-threatening — Severe Gastric Side Effects Include Stomach Paralysis, Gastroparesis, And Intestinal Blockages (9/1/23)

Severe Stomach Conditions in Patients Using Semaglutide Weight Loss Drugs From Novo Nordisk — Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis (9/13/23)

Ozempic, Wegovy, Other GLP-1 Semaglutide Weight-Loss Drugs Linked to Gastroparesis in Recent Medical Study — Researchers Compared Semaglutide Drugs, Such as Ozempic and Wegovy, to Contrave, a Non-GLP-1 Drug, in Weight-Loss Patients (10/24/23)

We are handling drug injury lawsuits for people who used Ozempic, Rybelsus, Wegovy, or Trulicity and then were diagnosed with the weight-loss drugs gastroparesis side effects.

[Read article in full at original source]

Ozempic / Rybelsus / Wegovy/ Trulicity

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic Intestinal Blockage and Obstruction Cases Increasing

By

The number of Ozempic intestinal blockage and obstruction cases, including ileus cases, that have been reported to the FDA during the first 6 months of 2023 was covered in this September 28, 2023 article, “FDA Adds New Warning for Ileus to Semaglutide (Ozempic) Label”, published September 28, 2023, on the HCPLive® website:

According to the US FDA’s Adverse Events Reporting System (FAERS) public dashboard, there have been 2951 total cases of adverse events associated with use of Ozempic during 2023 as of June 30, 2023. The majority of these cases are gastrointestinal-related events, which account for 1274 of the 2951 total cases.

Within the FAERS public dashboard, there were 6 total cases of ileus reported with use of [Ozempic], with 2 resulting in hospitalization. Of note, the number of cases reported so far in 2023 is more than double the total number of cases reported in 2019.

In September 2023 the Ozempic (semaglutide) drug label was updated to inform doctors and patients that adverse reaction reports concerning ileus, a gastrointestinal disorder, have been received for semaglutide during the time since Ozempic was first approved by the FDA in 2017. This September 2023 Ozempic label change can be found in part “6.3 Postmarketing Experience” of the Ozempic Full Prescribing Information document (“Revised: 9/2023” version).

We will watch for more information on Ozempic intestinal blockage and obstruction cases, including ileus cases, in the medical literature and from the FDA as well as other drug regulators worldwide.

At the present time, we are investigating Ozempic intestinal blockage and obstruction cases where there has been a diagnosis of gastroparesis, gastric stasis, or stomach paralysis as possible drug injury lawsuits to be filed against Novo Nordisk, the responsible pharmaceutical company. We are also looking into similar cases involving Rybelsus or Wegovy, two other semaglutide drugs from Novo Nordisk. All three of these drugs, Ozempic, Rybelsus, and Wegovy, are being used more and more for weight-loss purposes, as has been reported by the mainstream media during this past year.

[Read article in full at original source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis

By

In recent years we have seen an increasing number of adverse event reports for three Novo Nordisk semaglutide-containing drugs — Ozempic, Rybelsus, and Wegovy — that involve severe stomach conditions, including:

  • Gastroparesis
  • Gastric Stasis
  • Stomach Paralysis

The most common symptoms are nausea and vomiting, which can be severely disabling and can adversely impact the quality of life in patients suffering from these possible side effects of semaglutide-containing drugs such as Ozempic, Rybelsus, and Wegovy.

People experiencing gastroparesis, gastric stasis, or stomach paralysis often go to the emergency department/emergency room (ER) of their local hospital, sometimes several different times, before finally being admitted to the hospital.

While an ER doctor may determine that a person using one of the semaglutide-containing drugs has developed severe stomach conditions and then orders hospital admission, the actual medical diagnosis of gastroparesis or gastric stasis is usually made by a gastroenterologist, also called a GI doctor.

We are currently investigating drug injury lawsuits for people diagnosed with possible side effects of semaglutide-containing drugs such as Ozempic, Rybelsus, and Wegovy.

In more detail, these drug injury lawsuits involve someone who:

  1. Was actively using or recently stopped using Ozempic, Rybelsus, and Wegovy at the time they started to experience symptoms of these severe stomach conditions;
  2. Was diagnosed by a medical doctor with gastroparesis, gastric stasis, or stomach paralysis; and,
  3. Was hospitalized for those possible side effects of semaglutide-containing drugs such as Ozempic, Rybelsus, and Wegovy.

If we can assist you or someone you know, we encourage you to submit an online Case Evaluation Form. It is free, confidential, and there is no obligation. You will get a reply from us no later than the next business day.

In the alternative, you can email (TJL@LambLawOffice.com) or call (800-426-9535) attorney Tom Lamb to discuss the possible Ozempic, Rybelsus, or Wegovy drug injury lawsuit.

[Read article in full at original source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages

By

In the several years since Ozempic was approved by the FDA, there have been adverse event reports of Ozempic-related gastroparesis, stomach paralysis, and intestinal blockage cases in patients using Ozempic. Gastroparesis may also be called delayed gastric emptying. Gastroparesis is a long-term, chronic condition that can be irreversible even after a patient stops using Ozempic.

We point out that the current drug label for Ozempic does not warn about gastroparesis, stomach paralysis, and intestinal blockages or obstructions being potential side effects of Ozempic. As a result, patients are likely unaware that they are at risk for developing one of these severe gastric side effects, which can require hospitalization and surgery to treat.

Wegovy is a higher-dose version of Ozempic that is FDA-approved to treat obesity. Both of these relatively new drugs, from the pharmaceutical company Novo Nordisk, contain the active ingredient semaglutide. Wegovy has been linked to cases gastroparesis, stomach paralysis, and intestinal blockage, also. However, the current drug label for Wegovy (like Ozempic) does not warn about these severe gastric side effects.

We are investigating possible Wegovy and Ozempic drug injury lawsuits filed against Novo Nordisk based on this failure to warn doctors about those serious stomach or intestinal side effects. These Wegovy and Ozempic lawsuits involve gastroparesis, stomach paralysis, intestinal blockage, or intestinal blockage diagnosed in a patient while using Ozempic or Wegovy.

[Read article in full at original source]

Ozempic / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Our Other Websites

DrugInjuryWatch.com

LambLawOffice.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com